MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$43,082K
EPS
-$0.23
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
29,283
38,598
59,994*
40,520
General and administrative
12,907
14,266
23,551*
12,180
Acquired in-process research and development
-
-
-10,000*
5,000
Total operating expenses
42,190
52,864
73,545
57,700
Loss from operations
-42,190
-52,864
-73,545*
-57,700
Interest income
935
1,231
1,976*
1,685
Interest expense
1,820
1,854
978*
747
Other income (expense), net
-7
59
-57*
7
Total other income (expense)
-892
-564
940*
945
Net loss before income taxes
-43,082
-53,428
-72,606*
-56,755
Provision for income taxes
0
30
93*
0
Net loss
-43,082
-53,458
-72,699*
-56,755
Unrealized loss on marketable debt securities
0
0
-80*
24
Comprehensive loss
-43,082
-53,458
-72,779
-56,731
Basic EPS
-0.23
-0.3
-0.437
-0.35
Diluted EPS
-0.23
-0.3
-0.437
-0.35
Basic Average Shares
185,163,000
179,872,000
166,644,000
161,838,000
Diluted Average Shares
185,163,000
179,872,000
166,644,000
161,838,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$43,082K
(18.32%↑ Y/Y)
Net loss
-$43,082K
(18.30%↑ Y/Y)
Net loss before
income taxes
-$43,082K
(18.26%↑ Y/Y)
Loss from operations
-$42,190K
(21.93%↑ Y/Y)
Total other income
(expense)
-$892K
(-166.87%↓ Y/Y)
Interest income
$935K
Total operating
expenses
$42,190K
Interest expense
$1,820K
Other income
(expense), net
-$7K
(98.54%↑ Y/Y)
Research and development
$29,283K
General and
administrative
$12,907K
Buy us a coffee
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)